// App-Quantinova.ai

e18559 : Symptom assessment in patients with JAK inhibitor naive and JAK inhibitor failed myelofibrosis.

Researchers

Presenter

  • Yun Su

Principal Investigators

  • Adrian Woolfson

  • Josef T. Prchal

  • Kathleen Wyant Turnbull

  • Claire N. Harrison

  • Elias Jabbour

  • Robyn Marie Scherber

  • Alan Shields

  • Meaghan Krohe

  • Funke Ojo

  • Farrah Pompilus

  • Ruben A. Mesa

Medical Centers

  • Pfizer Inc, New York, NY

  • Pfizer Inc, New York, NY

  • University of Utah School of Medicine, Salt Lake City, UT

  • Pfizer Inc., Cambridge, MA

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Oregon Health and Science University, Portland, OR

  • Adelphi Values, Boston, MA

  • Mayo Clinic, Scottsdale, AZ

Locations

  • United States

  • United Kingdom

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Myelofibrosis

Biomarkers

  • Janus kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved